PT - JOURNAL ARTICLE AU - Hussey, Hannah AU - Davies, Mary-Ann AU - Heekes, Alexa AU - Williamson, Carolyn AU - Valley-Omar, Ziyaad AU - Hardie, Diana AU - Korsman, Stephen AU - Doolabh, Deelan AU - Preiser, Wolfgang AU - Maponga, Tongai AU - Iranzadeh, Arash AU - Engelbrecht, Susan AU - Wasserman, Sean AU - Schrueder, Neshaad AU - Boloko, Linda AU - Symons, Greg AU - Raubenheimer, Peter AU - Viljoen, Abraham AU - Parker, Arifa AU - Cohen, Cheryl AU - Jassat, Waasila AU - Lessells, Richard AU - Wilkinson, Robert J AU - Boulle, Andrew AU - Hsiao, Nei-yuan TI - Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy AID - 10.1101/2021.10.23.21265412 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.23.21265412 4099 - http://medrxiv.org/content/early/2021/10/26/2021.10.23.21265412.short 4100 - http://medrxiv.org/content/early/2021/10/26/2021.10.23.21265412.full AB - A novel proxy for the Delta variant, RNA-dependent RNA polymerase target delay in the Seegene Allplex™ 2019-nCoV PCR assay, was associated with higher mortality (adjusted Odds Ratio 1.45 [95%CI 1.13-1.86]), compared to presumptive Beta infection, in the Western Cape, South Africa (April-July 2021). Prior diagnosed infection and vaccination were protective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill & Melinda Gates and the Minderoo Foundations (INV-017293), and by a research Flagship grant from the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI). Additional support was provided by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC0010218), the UK Medical Research Council (FC0010218), and the Wellcome Trust (FC0010218) as well as Wellcome (203135, 222574).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Cape Town Research Ethics Committee (HREC 460/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors